Vertex Pharmaceuticals Reports Third-Quarter EPS of $2.56

Vertex Pharmaceuticals 3Q Rev $3.44B >VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance.“Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly di…